A5052052779- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Immunotherapy and Immune Responses
- Chronic Lymphocytic Leukemia Research
- Testicular diseases and treatments
- Acute Lymphoblastic Leukemia research
- Biosimilars and Bioanalytical Methods
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Treatment and Research
- Chronic Myeloid Leukemia Treatments
- Protein Degradation and Inhibitors
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Marine Sponges and Natural Products
- Histone Deacetylase Inhibitors Research
- Glioma Diagnosis and Treatment
- Chemotherapy-induced organ toxicity mitigation
- Monoclonal and Polyclonal Antibodies Research
- Ovarian cancer diagnosis and treatment
- Echinoderm biology and ecology
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Cancer Research and Treatments
- Cell death mechanisms and regulation
- Polyomavirus and related diseases
Universität Hamburg
2016-2025
University Medical Center Hamburg-Eppendorf
2016-2025
University Cancer Center Hamburg
2015-2025
Eppendorf (Germany)
2021-2024
The oncofetal antigen Claudin 6 (CLDN6) is highly and specifically expressed in many solid tumors, could be a promising treatment target. We report dose escalation results from the ongoing phase 1/2 BNT211-01 trial evaluating safety feasibility of chimeric receptor (CAR) T cells targeting CLDN6 with or without CAR-T cell-amplifying RNA vaccine (CARVac) at two levels (DLs) relapsed/refractory CLDN6-positive tumors. primary endpoints were tolerability, maximum tolerated recommended 2 (RP2D)....
Rationale of the trial Although use engineered T cells in cancer immunotherapy has greatly advanced treatment hematological malignancies, reaching meaningful clinical responses solid tumors is still challenging. We investigated safety and tolerability IMA202 a first-in-human, dose escalation basket human leucocyte antigen A*02:01 positive patients with melanoma-associated A1 (MAGEA1)-positive tumors. Trial design The 2+2 was an algorithmic based on maximally acceptable dose-limiting toxicity...
Liquid biopsies can be used in castration-resistant prostate cancer (CRPC) to detect androgen receptor splice variant 7 (AR-V7), a splicing product of the receptor. Patients with AR-V7-positive circulating tumor cells (CTCs) have greater benefit taxane chemotherapy compared novel hormonal therapies, indicating treatment-selection biomarker. Likewise, those pancreatic (PaCa),
Despite recent advances in the treatment of metastatic castration-resistant prostate cancer (CRPC), outcome patients remains poor due to development drug resistance. Thus, new drugs are urgently needed. We investigated efficacy, toxicity and mechanism action marine triterpene glycoside frondoside A (FrA) using CRPC cell lines vitro vivo. FrA revealed high efficacy human cells, while non-malignant cells were less sensitive. Remarkably, proliferation colony formation resistant enzalutamide...
Advanced urothelial carcinomas represent a considerable clinical challenge as they are difficult to treat. Platinum-based combination regimens obtain response rates ranging from 40 70% in first-line therapy of advanced carcinoma. In the majority cases, however, duration these responses is limited, and when progression occurs, outcome generally poor. Therefore, novel therapeutic strategies urgently needed. The purpose current research investigate anticancer effects mode action marine...
Analyze the outcomes of critically ill patients who developed new-onset organ dysfunction and received systemic chemotherapy during their ICU stay. Retrospective cohort study. A tertiary medical center in Germany with an Intensive Care Medicine department consists 11 intensive care units comprising 140 beds, serving all subspecialties adult medicine. 167 receiving oncological treatment from January 1st, 2015 to December 31st, 2021, a data cut-off on 2022. None. total were included. The...
<title>Abstract</title> Extramedullary multiple myeloma (EMD) is associated with low response rates, short progression-free survival and poor prognosis. CAR T cells bispecific antibodies (bsABs) have shown efficacy in relapsed but it remains uncertain whether one cell redirection strategy should be preferred. We retrospectively analyzed 80 patients EMD not adjacent to the bone treated ide-cel, cilta-cel, teclistamab or talquetamab at three academic centers Germany. All were heavily...
For patients with refractory or relapsed Burkitt lymphoma (BL), no standard therapy is available for second-line treatment to date. Nonfunctional caspases-dependent apoptosis pathways, inactivating p53 mutations and pro-survival autophagy prevent activity of conventional chemotherapy. Thus, new drugs bypassing these mechanisms resistance are required. Here, we investigated the efficacy marine natural compound frondoside A (FrA) in eight BL cell lines. FrA revealed cytotoxic effects all lines...
Abstract Background: BNT211 comprises two drug products, a chimeric antigen receptor (CAR)-T cell product candidate that targets the tumor specific claudin 6 (CLDN6) and CAR-T cell-Amplifying RNA Vaccine (CARVac). In mice, CARVac mediates expansion of adoptively transferred cells, improving their persistence functionality. aims to establish therapy for CLDN6-positive solid tumors. Methods: This first-in-human, open label, multi-center trial involves bifurcated 3+3 design with CLDN6 dose...
Abstract T cell receptor (TCR)-based adoptive therapy represents an innovative and promising treatment for pts with solid cancers who continue to have a high unmet medical need. This ongoing trial (NCT03686124) evaluates IMA203, autologous TCR-engineered (TCR-T) utilizing novel, pairing-enhanced TCR affinity specificity against HLA-A*02:01-presented peptide derived from PRAME. PRAME is multi-cancer target prevalence of 80-100% in cut. uveal melanoma, sarcoma subtypes, uterine ovarian cancer;...
// Sergey A. Dyshlovoy 1, 2, 3, * , Katharina Otte Winfried H. Alsdorf 1 Jessica Hauschild Tobias Lange 4 Simone Venz 5 Christiane K. Bauer 6 Robert Bähring Kerstin Amann 7 Ramin Mandanchi Udo Schumacher Jennifer Schröder-Schwarz Tatyana N. Makarieva 2 Alla G. Guzii Kseniya M. Tabakmakher Fedorov Larisa Shubina Igor E. Kasheverov 8 Heimo Ehmke Thomas Steuber 9 Valentin Stonik Carsten Bokemeyer Friedemann Honecker 10 Gunhild von Amsberg University Medical Center Hamburg-Eppendorf,...
Abstract Background High-dose (HD) methotrexate (MTX) is an essential component of treatment protocols in acute lymphoblastic leukemia, aggressive lymphoma, and osteosarcoma. However, delayed MTX clearance may lead to life-threatening toxicities. Administration supportive therapy for HD-MTX complex, insufficient care increases the risk toxicity. To improve patient safety, we investigated implementation a checklist urine alkalinization protocol addition standard during therapy. Materials...
2518 Background: We are developing a chimeric antigen receptor (CAR)-T cell therapy targeting claudin 6 (CLDN6), an oncofetal that is undetectable in healthy somatic tissue and highly expressed various solid cancers. Autologous CLDN6 CAR-T cells being tested alone combination with CLDN6-encoding Amplifying RNA Vaccine (CARVac), nanoparticulate vaccine designed to stimulate expand cells. Methods: The ongoing first-in-human trial BNT211-01 evaluates the safety feasibility of transfer ± CARVac...
<h3>Background</h3> BNT211 is a chimeric antigen receptor (CAR)-T cell product candidate that targets the tumor specific Claudin-6 (CLDN6). Preclinical studies demonstrated combining these engineered cells with CAR-T Amplifying RNA Vaccine (CARVac) leads to in vivo expansion of adoptively transferred cells, resulting their improved persistence and functionality. <h3>Methods</h3> This first-in-human, open label, multi-center trial involves bifurcated 3+3 design separate CLDN6 dose escalations...